Synageva BioPharma (GEVA) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
JPMorgan Downgrades Synageva BioPharma (GEVA) to Neutral
March 2, 2015 6:54 AM ESTJPMorgan downgraded Synageva BioPharma (NASDAQ: GEVA) from Overweight to Neutral with a price target of $88.00 (from $90.00).
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $98.73 yesterday.
... More